File:Ampligen-response-2016.jpg

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Ampligen-response-2016.jpg ‎(800 × 472 pixels, file size: 35 KB, MIME type: image/jpeg)

Summary[edit | edit source]

Title: (or description)[edit | edit source]

Ampligen (Rintatinamol) trial results summary. Figure 5. AMP-516 plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Reproduced from Strayer et al. Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME): Characteristics of responders to Rintatolimod. J Drug Res Dev 2015;1: doi http://dx.doiorg/10.16966/jdrd.103.
Key: ET - Exercise Tolerance test

Author: (or citation)[edit | edit source]

Mitchell, William M (June 2, 2016). "Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)". Expert Review of Clinical Pharmacology. 9 (6): 755–770. doi:10.1586/17512433.2016.1172960.
Disclosure: Author William Mitchell is Chairman of the board of AIM ImmunoTech, who have developed Ampligen.

Source: (e.g. internet address)[edit | edit source]

Figure 5.

Other information:[edit | edit source]

See also[edit | edit source]

Licensing[edit | edit source]

Creative Commons
attribution 		This file is licensed under the Creative Commons Attribution 4.0 International license.
You are free:
  • to share – to copy, distribute and transmit the work
  • to remix – to adapt the work
Under the following conditions:
  • attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current18:17, April 13, 2022Thumbnail for version as of 18:17, April 13, 2022800 × 472 (35 KB)Notjusttired (talk | contribs)==== Title: (or description) ==== Ampligen (Rintatinamol) trial results summary. Figure 5. AMP-516 plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Plot of ET differe...

You cannot overwrite this file.

There are no pages that use this file.

Metadata

This file contains additional information, probably added from the digital camera or scanner used to create or digitize it.

If the file has been modified from its original state, some details may not fully reflect the modified file.

Retrieved from "https://me-pedia.org/w/index.php?title=File:Ampligen-response-2016.jpg&oldid=237212"